Treating Retinopathy of Prematurity with Dexamethasone Eye Drops
Rattachement africain : se. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
PURPOSE: To estimate the effect of dexamethasone eye drops on the risk of progression from type 2 retinopathy of prematurity (ROP) to ROP requiring traditional treatments. DESIGN: Register-based cohort study. PARTICIPANTS: Preterm infants born before 30 weeks' gestation from 2015-2018 (control years) and from 2020-2021 (intervention years) registered in the Swedish Quality Register for ROP at 4 Swedish sites were included. In 1 of these sites, the intervention site, topical dexamethasone was introduced during the later period when type 2 ROP was diagnosed. METHODS: The frequency of traditional ROP treatments (laser ablation or intravitreal injection of anti-VEGF) was compared between the 2 periods at sites that had and had not introduced topical dexamethasone during the later period. Analyses were conducted both on infants with severe ROP and on all included infants. The difference-in-differences statistical method was used. MAIN OUTCOME MEASURES: The proportion of infants that required traditional ROP treatment in each group and the interaction odds ratio, adjusted for potential confounding factors. RESULTS: At the intervention site, the incidence of traditional ROP treatment fell from 23/32 (72%) to 4/32 infants (13%; P < 0.001) with severe ROP and from 23/409 (5.6%) to 4/217 screened infants (1.8%; P = 0.03). For the 3 control sites, the equivalent numbers were from 82/175 (47%) to 32/57 infants (56%; P = 0.22) and from 82/950 (8.6%) to 32/441 infants (7.3%; P = 0.38). The difference-in-differences analyses resulted in an adjusted interaction odds ratio of 0.05 (95% confidence interval, 0.01-0.22; P < 0.001) for infants with severe ROP, suggesting a markedly larger decline in occurrence of traditional ROP treatments at the intervention site. CONCLUSIONS: In this population of infants with severe ROP, the introduction of dexamethasone eye drops was associated with a significant reduction in the proportion of infants requiring traditional ROP treatments. A timely administration of low-dose dexamethasone eye drops may serve as a simple, cost-effective, and noninvasive intervention to reduce one of the leading causes of severe visual impairment worldwide. Further studies are needed to confirm our findings. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Treating Retinopathy of Prematurity with Dexamethasone Eye Drops
- Date Crossref
- 01/02/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Lund University Retinopathy of Prematurity Research Unit pays non établi dans la noticeUniversité ou école supérieure
-
Skåne University Hospital pays non établi dans la noticeÉtablissement de santé
-
Uppsala University Department of Surgical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
S:t Eriks Ögonsjukhus pays non établi dans la noticeÉtablissement de santé
-
Örebro University Hospital Department of Ophthalmology pays non établi dans la noticeÉtablissement de santé
-
University of Gothenburg Department of Clinical Neuroscience pays non établi dans la noticeUniversité ou école supérieure
-
Region Jönköpings län pays non établi dans la noticeOrganisme public
-
Umeå University Department of Clinical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Department of Clinical Neuroscience Section for Eye and Vision pays non établi dans la noticeÉtablissement de santé
-
St. Erik Eye Hospital Department of Pediatric Ophthalmology pays non établi dans la noticeÉtablissement de santé
-
Länssjukhuset Ryhov pays non établi dans la noticeInstitution
Retinopathy of Prematurity Research Unit — Lund University, Skåne University Hospital et Department of Surgical Sciences — Uppsala University, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.